EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Metformin sensitizes clonally evolved imatinib–geldanamycin-resistant CML models through AMPK–HSF1 and AMPK–RUNX1 signaling

Meher Bolisetti Gayatri, Abhayananda Behera, Rama Krishna Kancha, Dorababu Patchva, Nagaraj Velugonda, Sadasivudu Gundeti, Aramati Bindu Madhava Reddy

Cell Death · 2026-07 · 2 (3) · 100023

DOI: 10.1016/j.celld.2026.100023 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Death, 2026-07. Verfasst von Meher Bolisetti Gayatri und 6 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: India Ministry of Science & Technology Department of Biotechnology, Department of Science and Technology, Ministry of Science and Technology, India, University of Hyderabad.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multidrug resistance is one of the common features of the blast crisis (BC) phase of chronic myeloid leukemia (CML). One of the major pathways involved in drug resistance is the activation of the JAK2-STAT3 axis and the HSF1-mediated heat shock response. In this study, we investigated the role of metformin in sensitizing drug-resistant cells by modulating the pathways via the AMPK substrates HSF1 and RUNX1. Our experiments using clonally derived imatinib- and geldanamycin-dual-resistant K562 cell lines demonstrated that AMPK-mediated phosphorylation primes HSF-1 for ubiquitination, thereby inhibiting activation of the heat shock response. Additionally, AMPK phosphorylation inhibited the nuclear localization of RUNX1, increasing SOCS3 expression and leading to the loss of STAT3 activation. The data support the conclusion that metformin sensitizes resistant CML models and patient-derived PBMCs and indicate an AMPK–HSF1/RUNX1-linked mechanism.

Förderung

  • India Ministry of Science & Technology Department of Biotechnology
  • Department of Science and Technology, Ministry of Science and Technology, India
  • University of Hyderabad

Zitieren

APA

Gayatri, M. B., Behera, A., Kancha, R. K., Patchva, D., Velugonda, N., Gundeti, S., & Reddy, A. B. M. (2026). Metformin sensitizes clonally evolved imatinib–geldanamycin-resistant CML models through AMPK–HSF1 and AMPK–RUNX1 signaling. Cell Death, 2(3), 100023. https://doi.org/10.1016/j.celld.2026.100023

Vancouver

Gayatri MB, Behera A, Kancha RK, Patchva D, Velugonda N, Gundeti S, et al. Metformin sensitizes clonally evolved imatinib–geldanamycin-resistant CML models through AMPK–HSF1 and AMPK–RUNX1 signaling. Cell Death. 2026;2(3):100023. doi:10.1016/j.celld.2026.100023

BibTeX
@article{Gayatri2026,
  author = {Gayatri, Meher Bolisetti and Behera, Abhayananda and Kancha, Rama Krishna and Patchva, Dorababu and Velugonda, Nagaraj and Gundeti, Sadasivudu and Reddy, Aramati Bindu Madhava},
  title = {Metformin sensitizes clonally evolved imatinib–geldanamycin-resistant CML models through AMPK–HSF1 and AMPK–RUNX1 signaling},
  journal = {Cell Death},
  year = {2026},
  volume = {2},
  number = {3},
  pages = {100023},
  doi = {10.1016/j.celld.2026.100023}
}
Kostenlos starten →